1. Introduction
===============

14-3-3 proteins comprise seven isoforms (β, ε, γ, η, σ, τ/θ and ζ) and share highly conserved homology among all eukaryotic cells. They exert their influence by binding with Ser/Thr phosphorylated intracellular proteins, thereby affecting conformation, activity, subcellular localization and protein complex stability \[[@B1-cancers-07-00822],[@B2-cancers-07-00822],[@B3-cancers-07-00822],[@B4-cancers-07-00822],[@B5-cancers-07-00822]\]. 14-3-3 proteins have been shown to bind a variety of proteins, including Bad, receptors, histone deacetylases (HDACs), kinases and phosphatases. Thus, 14-3-3 proteins exert influence on diverse cell functions, including cell development, cell cycle regulation, DNA repair, proliferation, apoptosis, adhesion, motility and tissue response to injury \[[@B1-cancers-07-00822],[@B2-cancers-07-00822],[@B3-cancers-07-00822],[@B4-cancers-07-00822],[@B5-cancers-07-00822]\]. 14-3-3 proteins exhibit anti-apoptotic properties and protect cell survival through mitochondria-dependent mechanisms \[[@B3-cancers-07-00822],[@B4-cancers-07-00822],[@B5-cancers-07-00822],[@B6-cancers-07-00822],[@B7-cancers-07-00822],[@B8-cancers-07-00822]\]. It is therefore logical to hypothesize that 14-3-3 proteins are associated with malignancies. An increasing number of reports have indicated that some 14-3-3 isoforms are overexpressed and that 14-3-3 proteins are implicated in regulating tumor progression of various types of human malignancies \[[@B9-cancers-07-00822],[@B10-cancers-07-00822],[@B11-cancers-07-00822],[@B12-cancers-07-00822],[@B13-cancers-07-00822],[@B14-cancers-07-00822]\]. Elevated expression of selective 14-3-3 proteins is thus considered as having the potential to be tumor progression promoters.

2. Expression of 14-3-3 Proteins in HCC
=======================================

Several studies have indicated that 14-3-3β, 14-3-3ε, 14-3-3γ, 14-3-3σ (also known as stratifin) and 14-3-3ζ isoforms are overexpressed in hepatocellular carcinoma (HCC) \[[@B15-cancers-07-00822],[@B16-cancers-07-00822],[@B17-cancers-07-00822],[@B18-cancers-07-00822],[@B19-cancers-07-00822],[@B20-cancers-07-00822],[@B21-cancers-07-00822]\]. It was first demonstrated that increased 14-3-3ε expression is associated with a poorer overall and progression-free survival rate in HCC \[[@B15-cancers-07-00822]\]. It is worth noting that 14-3-3ε overexpression significantly correlates with extrahepatic metastasis \[[@B15-cancers-07-00822]\]. These results reveal that 14-3-3ε may contribute to cell survival regulation, proliferation, epithelial-mesenchymal transition (EMT) migration, as well as HCC invasion, which eventually lead to tumor growth and metastasis promotion. In addition, later studies reported that the expression of other 14-3-3 isoforms is elevated in HCC. Expression of 14-3-3γ has been implicated in promoting cell proliferation \[[@B22-cancers-07-00822],[@B23-cancers-07-00822]\], and results from a proteomics study have revealed that 14-3-3γ is detected in HCC \[[@B24-cancers-07-00822]\]. Increased 14-3-3β stimulates cell proliferation and tumor formation \[[@B25-cancers-07-00822]\], whereas knockdown of 14-3-3β reduces rat hepatoma cell proliferation and tumor growth \[[@B26-cancers-07-00822]\]. Various studies have indicated that 14-3-3β and 14-3-3γ are abundantly expressed and significantly associated with poorer survival rates and higher risks of HCC metastasis \[[@B16-cancers-07-00822],[@B17-cancers-07-00822]\].

14-3-3ζ is overexpressed in hepatoma cell lines and in tumors of HCC patients, whereas silencing of 14-3-3ζ by RNA interference suppresses tumor cell proliferation \[[@B18-cancers-07-00822]\]. It was reported that αB-crystallin complexes with and induces 14-3-3ζ expression, thereby activating downstream signaling to promote EMT and causing certain drug resistances in HCC \[[@B19-cancers-07-00822]\].

The reports of 14-3-3σ expression in tumors are controversial. Earlier studies have indicated that 14-3-3σ is activated by the tumor suppressor protein p53 \[[@B27-cancers-07-00822]\], and epigenetic silencing of 14-3-3σ by promoter methylation has been reported in various cancer cells \[[@B28-cancers-07-00822],[@B29-cancers-07-00822]\]. In contrast, an increasing number of recent studies have demonstrated that increased expression of 14-3-3σ promotes tumor progression \[[@B30-cancers-07-00822],[@B31-cancers-07-00822],[@B32-cancers-07-00822],[@B33-cancers-07-00822],[@B34-cancers-07-00822],[@B35-cancers-07-00822],[@B36-cancers-07-00822],[@B37-cancers-07-00822]\]. In HCC, eliminating 14-3-3σ expression by hypermethylation of CpG islands was reported in an earlier study \[[@B38-cancers-07-00822]\]. However, increased 14-3-3σ expression in HCC was shown in later reports \[[@B15-cancers-07-00822],[@B21-cancers-07-00822],[@B39-cancers-07-00822]\]. Taken together, these results suggest that 14-3-3 proteins are potential prognostic markers of HCC.

3. 14-3-3 Proteins Regulate HCC Cell Proliferation
==================================================

14-3-3 proteins activate Raf-1 kinase and subsequently induce the activity of mitogen-activated protein kinase (MAPK) and extracellular regulated kinase (ERK) signaling \[[@B40-cancers-07-00822],[@B41-cancers-07-00822],[@B42-cancers-07-00822]\]. Growth factors activate the mechanistic target of rapamycin complex 1 (mTORC1) through Akt-mediated phosphorylation of tuberous sclerosis protein 1/2 (TSC1/2), resulting in the formation of the TSC1/2 and 14-3-3 complex \[[@B43-cancers-07-00822]\]. Thus, 14-3-3 proteins may regulate multiple cellular functions, including cell proliferation, transformation and migration, through altering phosphoinositide 3-kinase (PI3K), MAPK and mTOR signaling.

14-3-3γ is abundantly expressed, and overexpression of 14-3-3γ induces polyploidization of lung cancer cells \[[@B44-cancers-07-00822]\]. Expression of 14-3-3γ is stimulated by IL-3, and 14-3-3γ overexpression promotes cell survival and growth by activating PI3K and MAPK signaling in hematopoietic cells \[[@B22-cancers-07-00822]\]. These results suggest that 14-3-3γ is a crucial factor to modulate cell proliferation. Result from a proteomic study by two-dimensional difference gel electrophoresis and mass spectrometry reveals that 14-3-3γ is one of the potential biomarker of HCC \[[@B24-cancers-07-00822]\]. A further study indicated that overexpression of 14-3-3γ is associated with extrahepatic metastasis and overall survival of HCC patients \[[@B16-cancers-07-00822]\]. 14-3-3γ is thus considered a potential factor that contributes to HCC tumor progression by modulating cell proliferation and survival.

A previous study indicated that 14-3-3ζ is significantly overexpressed in HCC cells and tissues \[[@B18-cancers-07-00822]\]. Suppression of 14-3-3ζ by siRNA inhibits HepG2 hepatoma cell proliferation, and depletion of 14-3-3ζ expression results in the reduction of the tumorigenicity of Huh-7 cells \[[@B18-cancers-07-00822]\]. Besides, silencing of 14-3-3ζ affects the chemosensitivity of HCC cells by regulating JNK and p38 signaling \[[@B18-cancers-07-00822]\]. However, the molecular mechanism for how 14-3-3ζ is involved in JNK/p38-regulating chemosensitivity remains unclear.

14-3-3β is implicated in the regulation of cell proliferation and migration. It was reported that overexpression of 14-3-3β induced cell proliferation, anchorage-independent growth and tumor growth of transformed cells via altering the activation of the MAPK signal pathway \[[@B17-cancers-07-00822]\]. Moreover, increased 14-3-3β expression is associated with promoting cell proliferation in distinct types of cancer cells \[[@B45-cancers-07-00822],[@B46-cancers-07-00822]\], whereas knockdown of 14-3-3β suppresses *in vitro* cell proliferation and *in vivo* tumor growth of rat hepatoma K2 cells \[[@B26-cancers-07-00822]\]. 14-3-3β binds and forms a complex with 14-3-3β interactant 1 (FBI1) and transcriptionally suppresses the expression of MAPK phosphatase-1, thereby activating MAPK signaling to promote tumorigenicity and metastasis \[[@B47-cancers-07-00822]\]. In addition, a further study focused on investigating the role of 14-3-3β on HCC tumor progression. Elevated 14-3-3β expression was significantly associated with higher incidence of metastasis and worse overall survival of HCC \[[@B17-cancers-07-00822]\]. In addition, overexpression of 14-3-3β promotes HCC cell migration and proliferation, whereas treatment of the MEK-1 inhibitor abolished 14-3-3β-induced cell proliferation and migration \[[@B17-cancers-07-00822]\]. These results suggest that 14-3-3β plays role as a promoting factor for cell proliferation of HCC.

4. Anti-Apoptotic Effects of 14-3-3
===================================

14-3-3 proteins protect cells from apoptosis by binding and retaining of phosphorylated Bad. Signaling from death insults leads to translocation of Bad and Bax to the mitochondrial membrane, where they form heterodimers with the anti-apoptotic Bcl-2 or Bcl-XL, thereby disrupting mitochondrial membrane potential and inducing permeability transition \[[@B48-cancers-07-00822],[@B49-cancers-07-00822],[@B50-cancers-07-00822]\]. Through their high binding affinity for phosphorylated Bad, 14-3-3 proteins represent a major class of cytosolic proteins that play a physiological role in controlling apoptosis via the mitochondrial pathway. It has been reported that Akt phosphorylates Bad at Ser-136, ribosomal s6 kinase (RSK) at Ser-112 and protein kinase A (PKA) at Ser-155 \[[@B51-cancers-07-00822],[@B52-cancers-07-00822],[@B53-cancers-07-00822],[@B54-cancers-07-00822],[@B55-cancers-07-00822]\]. Results from several studies suggest that phosphorylation at Ser-155 by PKA is a pre-requisite for Bad dissociation from Bcl-XL, and the dissociated Bad is subsequently phosphorylated at Ser-112 and/or Ser-136 to facilitate its binding to 14-3-3 proteins \[[@B56-cancers-07-00822]\].

14-3-3 also has been reported to interact with apoptosis signal resulting kinase 1 (ASK1). The ASK1 is a general mediator of cell death induced by many death stimuli, including tumor necrosis factor-α, Fas and some anticancer drugs. ASK1 specifically interacts with 14-3-3ζ via the site involving Ser-967 of ASK-1. Overexpression of 14-3-3ζ blocked ASK1-induced apoptosis, whereas disruption of ASK-1 with 14-3-3ζ interaction increased ASK1-induced apoptosis. The pro-apoptotic activity of ASK1 is antagonized by its binding to 14-3-3 proteins \[[@B57-cancers-07-00822],[@B58-cancers-07-00822]\].

Another anti-apoptotic property of 14-3-3 proteins is attributed to their binding of phosphorylated Raf-1 and protection of Raf-1 kinase activity \[[@B40-cancers-07-00822],[@B41-cancers-07-00822],[@B42-cancers-07-00822]\]. Raf-1 has been shown to be an important regulator of endothelial cell survival induced by vascular endothelial growth factor (VEGF) \[[@B59-cancers-07-00822]\]. RSK is phosphorylated by ERK1/2, and RSK is involved in Raf-1/MEK-mediated cell survival signaling \[[@B60-cancers-07-00822]\]. RSK has been shown to mediate cell survival by phosphorylating Bad at Ser-112 \[[@B60-cancers-07-00822],[@B61-cancers-07-00822]\]. RSKs also phosphorylate transcriptional activators, such as cAMP response element-binding protein (CREB) \[[@B61-cancers-07-00822]\]. Thus, binding of Raf-1 by 14-3-3 may play an important role in activating RSK, which, in turn, promotes survival by phosphorylating Bad and other transactivators.

5. 14-3-3 Proteins Contribute to HCC EMT
========================================

EMT is a complicated, but essential process for tumor metastasis progression. Loss or attenuation of E-cadherin expression serves as a hallmark for EMT, and it is frequently associated with tumor malignancy, metastasis, recurrence and patient survival rates \[[@B62-cancers-07-00822],[@B63-cancers-07-00822]\]. E-cadherin expression is downregulated by promoter methylation \[[@B64-cancers-07-00822],[@B65-cancers-07-00822]\] or transcriptional repressors, including Snail, Slug, Twist, Zeb-1, Zeb-2 and SIP1 \[[@B66-cancers-07-00822],[@B67-cancers-07-00822],[@B68-cancers-07-00822]\]. The activated transcription repressors bind to the E-box motif on the promoter region, thereby suppressing the transcriptional expression of E-cadherin \[[@B66-cancers-07-00822],[@B67-cancers-07-00822],[@B68-cancers-07-00822]\].

Overexpression of 14-3-3ε correlates with the extrahepatic metastasis of HCC \[[@B15-cancers-07-00822]\], implying that 14-3-3ε is potentially involved in regulating cancer cell EMT, migration and invasion. 14-3-3ε overexpression affects the expression of the EMT markers. It reduces E-cadherin levels and increases vimentin and *N*-cadherin levels \[[@B69-cancers-07-00822]\], whereas knockdown of 14-3-3ε by siRNA inhibits EMT \[[@B69-cancers-07-00822]\]. 14-3-3ε induces Snail and Zeb-1 expression, but has no significant effect on other E-cadherin repressors \[[@B69-cancers-07-00822]\]. Although knockdown of either Snail or Zeb-1 by siRNAs suppresses HCC cell migration, 14-3-3ε-reduced E-cadherin expression was selectively abolished by the knockdown of Zeb-1, but not of Snail \[[@B69-cancers-07-00822]\]. These results suggest that 14-3-3ε's regulation of EMT and cell migration is complicated and that multiple regulators or pathways are involved. 14-3-3ε is reversely correlated with E-cadherin in regards to the association of 14-3-3ε expression with clinicopathological parameters and E-cadherin levels in HCC tumors \[[@B69-cancers-07-00822]\]. Notably, a combination of 14-3-3ε-positive and E-cadherin-negative expression is significantly associated with higher incidences of metastasis and poorer overall survival, whereas E-cadherin-positive expression has an attenuated prognostic outcome in 14-3-3ε-positive HCC patients \[[@B69-cancers-07-00822]\]. These results support the notion that E-cadherin is a potential downstream factor regulated by 14-3-3ε expression in HCC. Thus, 14-3-3ε contributes to EMT regulation in HCC.

14-3-3 proteins were reported to interact with Snail and Ajuba in breast cancer and 293 cells \[[@B70-cancers-07-00822]\]. Snail contains two putative 14-3-3 binding motifs, selectively interacts with 14-3-3γ, 14-3-3ε, 14-3-3τ and 14-3-3η isoforms and weakly associates with the 14-3-3β isoform \[[@B70-cancers-07-00822]\]. These 14-3-3 isoforms interact with Snail and the co-repressor Ajuba forming a transcriptional complex that facilitates the suppression of E-cadherin, consequently promoting cancer cell EMT \[[@B70-cancers-07-00822]\]. However, whether 14-3-3 interacts with Snail or other repressors of E-cadherin in HCC remains unclear.

Partitioning defective 3 (Par-3) is one of the crucial factors involved in modulating cell polarity, consequently affecting EMT and migration. Par-3 participates in the polarity complex and regulates cell polarity through interacting with several GTP-bound regulators \[[@B71-cancers-07-00822],[@B72-cancers-07-00822],[@B73-cancers-07-00822]\]. Par-3 expression is increased in HCC and is associated with distant metastasis and poor overall survival rates in HCC patients \[[@B74-cancers-07-00822]\]. 14-3-3 (also known as Par-5 in nematodes and flies) interacts with Par-3 and controls cell polarity via a phosphorylation-dependent manner \[[@B75-cancers-07-00822]\]. Furthermore, expression of Par-3 is significantly correlated with 14-3-3ε expression \[[@B74-cancers-07-00822]\]. Thus, 14-3-3ε may synergize with Par-3 in controlling cell polarity, resulting in promoting HCC EMT and metastasis.

It has been shown that 14-3-3ζ collaborates with ErbB2 to promote tumor progression of breast cancer via EMT induction \[[@B76-cancers-07-00822]\]. 14-3-3ζ also promotes EMT by interacting and regulating TGFβ receptor signaling and the PI-3K subunit of p85 in breast cancer \[[@B76-cancers-07-00822],[@B77-cancers-07-00822]\]. 14-3-3ζ also plays an important role in HCC. 14-3-3ζ is overexpressed in HCC and promotes cell proliferation, whereas knockdown of 14-3-3ζ suppressed cell proliferation via the activation of c-Jun N-terminal kinase (JNK) signaling \[[@B35-cancers-07-00822]\]. 14-3-3ζ was identified as one of the αB-crystallin-interacting proteins \[[@B36-cancers-07-00822]\]. αB-Crystallin belongs to the mammalian small heat shock protein superfamily, and it functions as a chaperone to protect cells from stress-induced damage \[[@B78-cancers-07-00822]\]. Expression of αB-crystallin and 14-3-3ζ are increased in HCC, and overexpression of αB-crystallin induces EMT and enhances resistance to sorafenib via ERK signal pathway activation \[[@B36-cancers-07-00822]\]. Moreover, αB-crystallin co-localizes and directly binds with 14-3-3ζ, consequently enhancing the stability of 14-3-3ζ and inducing Slug expression to promote HCC's EMT process \[[@B36-cancers-07-00822]\]. In conclusion, increased expression of selective 14-3-3 isoforms, including 14-3-3ε and 14-3-3ζ, induces specific signaling and regulator factors that facilitate EMT, cell migration and HCC tumor metastasis.

6. 14-3-3 Proteins Promote HCC Cell Migration
=============================================

Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase associated with and activated by integrins. FAK stimulates downstream signaling to regulate cell adhesion, migration and apoptosis \[[@B79-cancers-07-00822],[@B80-cancers-07-00822],[@B81-cancers-07-00822],[@B82-cancers-07-00822]\]. FAK is overexpressed in HCC and is a potential prognostic factor predicting worse overall survival rates and higher incidences of metastasis \[[@B83-cancers-07-00822]\]. It was reported that expression of FAK is dually regulated by p53 and NFκB \[[@B84-cancers-07-00822],[@B85-cancers-07-00822]\]. Activated NFκB bound to the binding site on the FAK promoter region induces FAK expression and enhances cell migration \[[@B84-cancers-07-00822],[@B85-cancers-07-00822]\]. Expression of FAK is tightly correlated with 14-3-3ε, and the positive expression of either 14-3-3ε or FAK is associated with the tumor size and extrahepatic metastasis of HCC \[[@B86-cancers-07-00822]\]. 14-3-3ε induces FAK expression and promoter activity. Transiently-forced expression of 14-3-3ε induces nuclear translocation of NFκB, as well as enhancing the binding capacity of NFκB to the FAK promoter \[[@B86-cancers-07-00822]\]. FAK is a crucial factor regulating cell migration, and 14-3-3ε promotes cell migration via the activation of the NFκB/FAK pathway in HCC.

14-3-3β has been implicated in modulating cell proliferation, migration and tumor growth in HCC \[[@B34-cancers-07-00822]\]. Expression of 14-3-3β in HCC tumors is elevated, and its expression is significantly associated with distant metastasis, whereas only rare incidences of metastasis were found in 14-3-3β-negative HCC patients \[[@B34-cancers-07-00822]\]. These results suggest that 14-3-3β plays an important role in promoting HCC tumor migration, invasion and metastasis. Forced expression of 14-3-3β increases HCC cell migration, proliferation, anchorage-independent growth and *in vivo* tumor growth \[[@B34-cancers-07-00822]\]. These effects are abolished by siRNA knockdown of 14-3-3β or treatment with pharmacological inhibitors of MEK-1/2 \[[@B34-cancers-07-00822]\]. It has been shown that 14-3-3β binds and maintains the activity of Raf-1, thereby enhancing Raf/MEK/ERK signaling \[[@B87-cancers-07-00822],[@B88-cancers-07-00822]\]. These studies imply that 14-3-3β is a potential effector promoting HCC progression via the MAPK signal pathway.

14-3-3σ plays a "bipolar" role in HCC. Although frequent hypermethylation of 14-3-3σ was found \[[@B55-cancers-07-00822]\], studies indicate that 14-3-3σ is increased in HCC \[[@B37-cancers-07-00822],[@B38-cancers-07-00822],[@B56-cancers-07-00822]\]. It has been reported that expression of 14-3-3σ correlates to the histology grade and micro-vascular thrombi of HCC \[[@B37-cancers-07-00822]\]. These results suggest that 14-3-3σ contributes to facilitating HCC cancer cell migration and invasion. Moreover, 14-3-3σ overexpression increases the expression of heat shock factor-1α (HSF-1α) and its downstream factor, HSP70, and consequently enhances cell migration. Knockdown of either HSF-1α or HSP70 eliminates 14-3-3σ-induced migration \[[@B37-cancers-07-00822]\]. In addition, 14-3-3σ-induced HSF-1α/HSP70 expression is regulated by β-catenin. 14-3-3σ enhances β-catenin levels, and knockdown of β-catenin abrogates 14-3-3σ-induced cell migration \[[@B37-cancers-07-00822]\]. These results suggest that regulation of the 14-3-3σ/β-catenin/HSF-1α/HSP70 cascade modulates HCC cell migration.

Intriguingly, 14-3-3σ was reported to contribute to cell invasion and metastasis in selective subtypes of breast cancer. Although the expression of 14-3-3σ is silenced in most types of breast cancer, 14-3-3σ stabilizes a soluble complex of actin and intermediate filaments to enhance cell invasion of the more aggressive and malignant breast cancers \[[@B89-cancers-07-00822]\]. 14-3-3σ expression is significantly correlated with poor clinical outcomes of basal-like subtype breast cancer. This was seen by analyzing the association of 14-3-3σ with breast cancer clinicopathological characteristics \[[@B89-cancers-07-00822]\]. These results suggest that 14-3-3σ is involved in cancer cell aggressiveness and tumor metastasis.

7. Conclusions
==============

Selective 14-3-3 isoforms are overexpressed and are potential prognostic markers of HCC. 14-3-3 isoforms contribute to HCC EMT and migration/invasion and are associated with a higher risk of extrahepatic metastasis ([Table 1](#cancers-07-00822-t001){ref-type="table"}). Overexpression of 14-3-3 proteins is thus a potential effector and can serve as a diagnostic marker for the more malignant types of HCC. 14-3-3 isoforms form homo-dimers or hetero-dimers that interact with their ligand proteins through Ser/Thr phosphorylation. As 14-3-3β, 14-3-3ε, 14-3-3σ and 14-3-3ζ isoforms are overexpressed in HCC, they may form different types of dimmers that interact with common or distinct partner proteins, thereby regulating joint or specific signaling and downstream targets. This may explain the specificity of select 14-3-3 isoform expression in different tissues or malignancies. In summary, 14-3-3ε and 14-3-3ζ contribute to HCC EMT by suppressing E-cadherin via Zeb-1 and αB-crystallin/Slug regulation, respectively. Additionally, 14-3-3β, 14-3-3γ and 14-3-3σ promote cell migration and proliferation of HCC mediated by activating Raf/MEK/ERK, PI3K/Akt signaling and increasing β-catenin/HSF-1α/HSP70 expression. The signaling pathways of JNK and p38/MAPK are involved in modulating 14-3-3ζ-associated chemosensitivity of HCC cells. Thus, 14-3-3 isoforms regulate cell proliferation, EMT and cell migration of HCC by synergistic networks to promote HCC tumor progression ([Figure 1](#cancers-07-00822-f001){ref-type="fig"}). Finally, expression of 14-3-3ζ is associated with sorafenib resistance, and 14-3-3σ is considered a potential target for drug resistance. In conclusion, expression of particular 14-3-3 isoforms is a potential prognostic marker for clinical outcomes of HCC. Targeting selective 14-3-3 isoforms and related effectors can be beneficial in developing therapeutic strategies for HCC. We therefore conclude that 14-3-3 proteins are promising prognostic markers and therapeutic targets of HCC.

cancers-07-00822-t001_Table 1

###### 

Studies related to 14-3-3 proteins in HCC.

  Ref.                                          Year   Isoform   Result
  --------------------------------------------- ------ --------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Iwata *et al.* \[[@B55-cancers-07-00822]\]    2000   14-3-3σ   Promoter of 14-3-3σ is hypermethylated, and 14-3-3σ is downregulated in HCC
  Komiya *et al.* \[[@B61-cancers-07-00822]\]   2008   14-3-3β   14-3-3β promotes tumorigenicity and metastasis in rat hepatoma
  Chen *et al.* \[[@B56-cancers-07-00822]\]     2010   14-3-3σ   14-3-3σ is detected in HCC
  Ko *et al.* \[[@B32-cancers-07-00822]\]       2011   14-3-3ε   14-3-3ε is overexpressed and associates with extrahepatic metastasis and survival of HCC
  Ko *et al.* \[[@B33-cancers-07-00822]\]       2011   14-3-3γ   14-3-3γ is overexpressed and associates with extrahepatic metastasis and survival of HCC
  Liu *et al.* \[[@B34-cancers-07-00822]\]      2011   14-3-3β   14-3-3β is overexpressed and associates with extrahepatic metastasis and survival of HCC; 14-3-3β promotes cancer cell migration, proliferation and tumor growth of HCC
  Choi *et al.* \[[@B35-cancers-07-00822]\]     2011   14-3-3ζ   14-3-3ζ is overexpressed in HCC. Silencing of 14-3-3ζ inhibits cell proliferation of HCC
  Jan *et al.* \[[@B74-cancers-07-00822]\]      2013   14-3-3ε   14-3-3ε expression is correlated with Par-3 in HCC
  Liu *et al.* \[[@B69-cancers-07-00822]\]      2013   14-3-3ε   14-3-3ε contributes to EMT in HCC cells; 14-3-3ε expression is reverse correlated with E-cadherin in HCC; a combination of 14-3-3ε/E-cadherin expression is associated with the prognosis of HCC
  Huang *et al.* \[[@B36-cancers-07-00822]\]    2013   14-3-3ζ   14-3-3ζ complexes with αB-crystallin to promote EMT and enhance resistance to sorafenib of HCC
  Ko *et al.* \[[@B85-cancers-07-00822]\]       2013   14-3-3ε   14-3-3ε induces FAK expression, and 14-3-3ε expression is correlated with FAK in HCC
  Liu *et al.* \[[@B37-cancers-07-00822]\]      2014   14-3-3σ   14-3-3σ is overexpressed and promotes cell migration of HCC
  Zhang *et al.* \[[@B38-cancers-07-00822]\]    2014   14-3-3σ   14-3-3σ is overexpressed in HCC

HCC, hepatocellular carcinoma; EMT, epithelial-mesenchymal transition.

![Illustrated scheme of networks for 14-3-3 and regulated downstream effectors in hepatocellular carcinoma EMT, cell migration and proliferation.](cancers-07-00822-g001){#cancers-07-00822-f001}
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